Project Grant R01AI187352
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $710,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Georgia Southern University Research & Service Foundation Inc. The grant aims to develop comprehensive morphological and molecular tools to effectively identify closely related Hyalomma tick species that are vectors of the Crimean-Congo Hemorrhagic Fever (CCHF) virus. The key products and services to be delivered...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $232,415 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis. The goal of this 2-year award, with a period of performance from November 2024 to October 2026, is to develop a highly potent monoclonal antibody that can neutralize the cytomegalovirus (CMV)-encoded interleukin-10 (IL-10) protein, in order to prevent primary CMV infection and reduce the...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $134,577 project grant to the University of California, Los Angeles (UCLA) on January 26, 2025. The grant supports research to elucidate the molecular mechanisms by which encephalitic alphaviruses, such as Sindbis and Chikungunya viruses, can cross the blood-brain barrier and invade the central nervous system. Utilizing a stem...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,047,991 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Rector & Visitors of the University of Virginia. The grant, awarded on September 12, 2025, will fund research to investigate the molecular basis for paired receptor signaling in antiviral natural killer (NK) cells during murine cytomegalovirus (MCMV) infection. The research aims to delineate how NK cell receptor...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $972,583 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Research Institute at Nationwide Children's Hospital in Ohio. The grant, titled "Defining Successful Intrahepatic CD4+ T Cell Responses Against the Hepatitis C Virus," aims to study protective CD4+ T cell responses in order to develop an effective vaccine against chronic Hepatitis C virus (HCV) infection....
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Partillion Bioscience Corp, a biotechnology company based in Los Angeles, California. The grant, funded under NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of advanced workflows utilizing Partillion's specialized hydrogel microparticle technology called "nanovials". The goal is to enable ultra high-throughput screening and functional...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,379,954 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant, awarded on August 21, 2025, supports research to engineer durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development. The project aims to systematically study the effects of immunogen affinity, valency, adjuvants, vaccine platforms, and...
- The University of California, San Diego (UCSD) was awarded a $3,194,992.00 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant, awarded on July 16, 2025, supports research to study the roles and regulation of tissue-resident CD8 T cells during a persistent viral infection. The research aims to investigate the mechanisms that allow immune cells to adapt and maintain a long-term...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, has awarded a $720,588 Project Grant to the Regents of the University of Minnesota. The grant supports the "Development of Broadly Protective Vaccines Against New World Arenaviruses" project, which aims to leverage the Pichinde virus vaccine vector to develop safe and effective vaccines against pathogenic New World arenaviruses, such as the...
- The University of California, San Francisco (UCSF) was awarded a $675,962 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of the grant is to characterize the interaction between human and vector behaviors in order to enhance the impact of malaria control interventions in Uganda. The project will integrate rigorous human behavioral and entomological monitoring data to elucidate...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $738,880 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the Regents of the University of California at Riverside. The grant funding will support research to identify and characterize protective antibodies against Crimean-Congo Hemorrhagic Fever Virus (CCHFV), a potentially fatal virus that has been rapidly spreading across parts of Europe, Asia, and Africa. The project aims to reveal the protective attributes of non-neutralizing monoclonal antibodies targeting the CCHFV viral proteins GP38 and NP, with the goal of developing new vaccine and therapeutic strategies against CCHFV and other nairovirus infections. The grant period runs from September 3, 2025 through August 31, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $738.9k | 9/3/25 |